Ambry Genetics Announces Settlement in BRCA1/2 Gene Patent Infringement Case

FOR IMMEDIATE RELEASE

Ambry Genetics
15 Argonaut
Aliso Viejo, CA 92656

Aliso Viejo, CA – February 2, 2015 – Ambry Genetics (“Ambry”) announces a settlement agreement that ends the BRCA1 and BRCA2 gene patent infringement litigation against Ambry that began on July 9, 2013. The case is University of Utah Research Foundation, et al., v. Ambry Genetics Corporation, United States District for the District of Utah, Case No. 2:13-cv-00640-RJS.

Under this agreement the plaintiffs, including Myriad Genetics, the University of Utah Research Foundation, the Trustees of the University of Pennsylvania, HSC Research and Development LP, and Endorecherche, Inc. and Ambry agreed to dismiss with prejudice their respective claims and counterclaims against one another in the BRCA1 and BRCA2 gene patent infringement litigation. Additionally, the Patent Owners granted a covenant to not sue Ambry under the patents asserted in the litigation proceedings. The decision to settle occurs after the United States Court of Appeals for the Federal Circuit held on December 17, 2014 that claims from three of the patents covering DNA-based BRCA1 and BRCA2 tests Myriad was asserting against Ambry did not contain subject matter eligible for patent protection.

Ambry Genetics was represented by McDermott Will & Emery before the Federal Circuit Court of Appeals and in the Utah district court litigation by McDermott Will & Emery and TraskBritt.


About Ambry Genetics ®

Ambry Genetics is a leader in clinical diagnostic and software solutions, combining both to offer the most comprehensive genetic testing menu in the industry. Ambry is both College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified. As part of the Konica Minolta family, Ambry is responsibly applying new technologies to the clinical molecular diagnostics market to bring about precision medicine. For more information about Ambry Genetics, visit www.ambrygen.com.

Press Contact:
Dina Scaglione
Director, Marketing
dscaglione@ambrygen.com
949 457 4355

Search Results

Start your search...